Minimal residual disease in multiple myeloma: Bringing the bench to the bedside Journal Article
| Authors: | Mailankody, S.; Korde, N.; Lesokhin, A. M.; Lendvai, N.; Hassoun, H.; Stetler-Stevenson, M.; Landgren, O. |
| Article Title: | Minimal residual disease in multiple myeloma: Bringing the bench to the bedside |
| Abstract: | Outcomes for patients with multiple myeloma (MM) have improved substantially in the past decade, with improvements in both progression-free survival and overall survival. Many patients are now achieving a complete response to treatment, and consequently highly sensitive assays are needed for detection of minimal residual disease (MRD) in patients with MM. Results of multicolour flow cytometry and deep-sequencing studies suggest that among patients achieving a complete response, MRD-negative status is associated with significant improvements in progression-free survival and overall survival. Despite the increasing need for MRD testing in patients with MM, considerable heterogeneity in techniques for MRD detection hinders the clinical interpretation of their results. The criteria used to define MRD, strengths and weaknesses of the major types of tests (flow cytometry versus molecular testing), and the optimal sample type (bone marrow aspirate versus peripheral blood) are all unresolved dilemmas in MRD testing. This Review presents an overview of the various techniques for MRD detection in patients with MM. In addition, this article discusses challenges and opportunities for the routine use of MRD testing, possible future directions for clinical trials and implications for drug approval processes. © 2015 Macmillan Publishers Limited. |
| Keywords: | immunohistochemistry; treatment response; overall survival; prednisone; review; doxorubicin; cancer growth; flow cytometry; stem cell factor receptor; progression free survival; multiple cycle treatment; multiple myeloma; cyclophosphamide; dexamethasone; melphalan; vincristine; autologous stem cell transplantation; carmustine; plasma cell; cd20 antigen; blood; bone marrow biopsy; minimal residual disease; cd19 antigen; cd28 antigen; cd45 antigen; cd38 antigen; pre b lymphocyte; cd27 antigen; syndecan 1; mast cell; cd56 antigen; next generation sequencing; cancer prognosis; human; priority journal |
| Journal Title: | Nature Reviews Clinical Oncology |
| Volume: | 12 |
| Issue: | 5 |
| ISSN: | 1759-4774 |
| Publisher: | Nature Publishing Group |
| Date Published: | 2015-05-01 |
| Start Page: | 286 |
| End Page: | 295 |
| Language: | English |
| DOI: | 10.1038/nrclinonc.2014.239 |
| PROVIDER: | scopus |
| PUBMED: | 25622976 |
| PMCID: | PMC7712493 |
| DOI/URL: | |
| Notes: | Export Date: 3 June 2015 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work